Abstract: The present invention relates to the identification of novel panels and combinations of biomarkers for ovarian cancer. An in vitro method is provided for detecting, predicting or monitoring ovarian cancer in a subject, wherein said method comprises determining in a sample from said subject the levels of the biomarkers in a panel comprising: TACSTD2, PROK1, MSMB, MUC-16, WFDC2, FR-alpha, and KRT19. More broadly, biomarkers may be selected and used from this list in variations combinations with each other and with other biomarkers. Also provided are sets of reagents for use in such methods.

Abstract: The present invention relates to a method and kit for quantitative and qualitative determination of human papillomavirus, HPV, in a sample. More precisely, for quantitative and qualitative determination of oncogenic HPV to predict the risk of HPV infection resulting in cervical carcinoma. The method and kit enable simultaneous measurement of several oncogenic HPV types.

Abstract: The present invention relates to a method for estimating the risk for development of carcinoma in an individual. More precisely, for estimating the cancer risk in an individual being exposed to human papilloma virus(es) (HPV). The method comprises (i) identification of one or more of said HPV or groups thereof in a sample from said human being; (ii) calculating the amount of HPV of each type or group in the sample and normalising the values to the amount of cells sampled; (iii) estimating the risk for each of the HPV or groups of HPV by comparing each viral titer value from (ii) with type or group specific standard curves for each viral type or group with risk estimation values; and (iv) estimating the combined risk for carcinoma development for the human being from the individual risk estimation curves of the different viral types.

Abstract: The present invention relates to a method and kit for quantitative and qualitative determination of human papillomavirus, HPV, in a sample. More precisely, for quantitative and qualitative determination of oncogenic HPV to predict the risk of HPV infection resulting in cervical carcinoma. The method and kit enable simultaneous measurement of several oncogenic HPV types.

Abstract: The present invention relates to a method for estimating the risk for development of carcinoma in an individual. More precisely, for estimating the cancer risk in an individual being exposed to human papilloma virus(es) (HPV). The method comprises (i) identification of one or more of said HPV or groups thereof in a sample from said human being; (ii) calculating the amount of HPV of each type or group in the sample and normalising the values to the amount of cells sampled; (iii) estimating the risk for each of the HPV or groups of HPV by comparing each viral titer value from (ii) with type or group specific standard curves for each viral type or group with risk estimation values; and (iv) estimating the combined risk for carcinoma development for the human being from the individual risk estimation curves of the different viral types.

Abstract: The present invention is within the medical field. More precisely, the invention relates to a method and kit for defection of mutations/polymorphisms in human mitochondrial DNA sequences and specifically to the use of mitochondrial DNA variants (polymorphisms) with high mutation frequency to be employed in the comparison of biological samples with samples of known origin in the purpose of, for example, human identification or forensic genetics.

Abstract: The present invention is within the fields of human origins, medicine and evolutionary biology. More precisely, the invention relates to a method and kit for determining the geographic or population origin of a human based on mitochondrial DNA sequences and specifically to the use of mitochondrial DNA variants (polymorphisms) from the complete human mitochondrial genome. This information is employed in the comparison of biological samples with samples of known origin or with a database of mitochondrial genome sequences.

Abstract: The present invention is within the field of early cancer prediction. More closely, the invention relates to a method and kit for predicting virus-associated cervical cancer in a human subject. In the method the amount of viral nucleic acid is normalized in relation to the amount of sample from a human subject. Using specific primers and probes in a DNA amplification kit of the invention, a value of relative viral load is obtained which enables prediction of risk of cervical cancer several years before any symptoms thereof.